Speaker illustration

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

Member of:

European Society of Cardiology

Kausik Ray FESC is Professor of Public Heath, Director of the Imperial Centre for CVD Prevention, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials Imperial College London and Consultant Cardiologist. He received his medical education Birmingham Univ, MD from Sheffield Univ, a fellowship at Harvard Medical School and finally an MPhil in Epidemiology at Cambridge Univ. He is current president of the EAS and national CVD prevention lead for the NIHR ARC. Professor Ray: is the lead for the 70 country FH Studies Collaboration the only global registry of FH, PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London. Professor Ray has led and participated in several novel therapies for hypercholesterolaemia and diabetes. Voted by Clarivate as among the top 1% of authors cited in clinical medicine globally H Index 84, i10 218 and ~ 90,000 citations.

How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options

Event: ESC Congress 2022

Topic: Cardiovascular Pharmacotherapy

Session type: Symposium

Thumbnail

GLP-1 RAs: more than just glucose-lowering agents

Event: ESC Congress 2022

Topic: Diabetes and the Heart

Session type: Satellite Symposium

Thumbnail

Cholesterol efflux explained: a potential role in clinical outcomes

Event: ESC Congress 2022

Topic: Acute Coronary Syndromes

Session type: Satellite Symposium

Thumbnail

Late Breaking Science in Prevention

Event: ESC Congress 2021 - The Digital Experience

Topic: Lipids

Session type: Late-Breaking Science

Thumbnail

Add on to take back control: Combining lipid lowering therapies for the management of high and very high risk patients

Event: ESC Congress 2021 - The Digital Experience

Topic: Lipids

Session type: Satellite Symposium

Thumbnail

Redefining intensive LDL-c management in high risk patients: The case for combination therapy

Event: ESC Congress 2021 - The Digital Experience

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

Rapid fire abstracts - Population Science and Public Health

Event: ESC Preventive Cardiology 2021

Topic: Risk Factors and Prevention

Session type: Abstract Sessions

Thumbnail

PCSK9 inhibitors: let’s get real

Event: ESC CONGRESS 2019

Topic: Myocardial Disease

Session type: Satellite Symposium

Thumbnail

PCSK9 inhibitors: let’s get real

Event: ESC CONGRESS 2019

Topic: Myocardial Disease

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

Epigenetics: a new pathway to tackle residual risk?

Event: ESC CONGRESS 2019

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

This platform is supported by

logo Novo Nordisk